

| | | | | | | | | | | |
|---|--------|--|---|---------------|---|---|----------------------------|--------------------------------------|---------------------------|--|
| | | | | | | | ©Afia Inc 2010 | | | |
| Meaningful Use - Stage 1 | | | | | | | | | | |
| The following outlines the FINAL Meaningful Use criteria for ARRA stimulus funding as of 7/13/2010. These are applicable to Eligible Professionals Only | | | | | | | | | | |
| | Number | Outcome Priority | MU Category | Brief Measure | Definition | Measure | Unique Patient Denominator | Actions in Certified EHR Denominator | Yes/No Attestation | |
| CORE SET | | | | | | | | | X | |
| Eligible Professionals required to satisfy all core set of objectives | | | | | | | | | X | |
| | 1 | Improving quality, safety, efficiency, and reducing health disparities | CPOE - Computerized provider order entry | 30% | Use CPOE for medication orders directly entered by any licensed healthcare professional who can enter orders into the medical record per state, local and professional guidelines | More than 30% of unique patients with at least one medication in their medication list seen by the EP have at least one medication order entered using CPOE | | | | |
| | 2 | | Implement drug-drug and drug allergy interaction checks | Enabled | Implement drug-drug and drug-allergy interaction checks | The EP has enabled this functionality for the entire EHR reporting period | | | Yes | |
| | 3 | | ePrescribing | 40% | Generate and transmit permissible prescriptions electronically (eRx) | More than 40% of all permissible prescriptions written by the EP are transmitted electronically using certified EHR technology | | X | | |
| | 4 | | Demographics | 50% | Record Demographics: o preferred language o gender o race o ethnicity o date of birth | More than 50% of all unique patients seen by the EP have demographics recorded as structured data | X | | | |
| | 5 | | Problem List | 80% | Maintain an up-to-date problem list of current and active diagnoses | More than 80% of all unique patients seen by the EP have at least one entry or an indication that no problems are known for the patient recorded as structured data | X | | | |
| | 6 | | Medication List | 80% | Maintain active medication list | More than 80% of all unique patients seen by the EP have at least one entry (or an indication that the patient is not currently prescribed any medication) recorded as structured data | X | | | |
| | 7 | | Medication Allergy List | 80% | Maintain active medication allergy list | More than 80% of all unique patients seen by the EP have at least one entry (or an indication that the patient has no known medication allergies) recorded as structured data | X | | | |
| | 8 | | Vital Signs | 50% | Record and Chart changes in vital signs: o Height o Weight o Blood pressure o Calculate and display: BMI o Plot and display growth charts for children 2-20 years, including BMI. | For more than 50% of all unique patients age 2 and over seen by the EP, height, weight and blood pressure are recorded as structured data | X | | | |
| | 9 | | Smoking Status | 50% | Record smoking status for patients 13 years old or older | More than 50% of all unique patients 13 years old or older seen by the EP have smoking status recorded as structured data | | X | | |
| | 10 | | Clinical Decision Support | One Rule | Implement one clinical decision support rule relevant to specialty or high clinical priority along with the ability to track compliance that rule along with the ability to track compliance with those rules | Implement one clinical decision support rule | | | Yes | |
| | 11 | | Calculate and Transmit CMS Quality Measures | 6 measures | Report ambulatory quality measures to CMS or the States | For 2011, provide aggregate numerator, denominator, and exclusions through attestation as discussed in section II(A)(3) of this final rule For 2012, electronically submit the clinical quality measures as discussed in section II(A)(3) of this final rule | | | Yes 2011, Electronic 2012 | |

Meaningful Use - Stage 1

The following outlines the FINAL Meaningful Use criteria for ARRA stimulus funding as of 7/13/2010. These are applicable to Eligible Professionals Only

| Number | Outcome Priority | MU Category | Brief Measure | Definition | Measure | Unique Patient Denominator | Actions in Certified EHR Denominator | Yes/No Attestation |
|---|--|--|--|--|--|----------------------------|--------------------------------------|--------------------|
| 12 | Engage patients and families in their health care | Electronic Copy of Health Information | 50% | Provide patients with an electronic copy of their health information (including diagnostic test results, problem list, medication lists, medication allergies), upon request | More than 50% of all patients of the EP who request an electronic copy of their health information are provided it within 3 business days | | X | |
| 13 | | Clinical Summaries for each office visit | 50% | Provide summary care record for each transition of care and referral | Clinical summaries provided to patients for more than 50% of all office visits within 3 business days | | X | |
| 14 | Improve care coordination | Exchange Key Clinical Information | One Test | Capability to exchange key clinical information (for example, problem list, medication list, medication allergies, diagnostic test results), among providers of care and patient authorized entities electronically (for example, problem list, medication list, allergies, diagnostic test results), among providers of care and patient authorized entities electronically | Performed at least one test of certified EHR technology's capacity to electronically exchange key clinical information | | | Yes |
| 15 | Ensure adequate privacy and security protections for personal health information | Privacy/Security | Conduct or review Security Risk Analysis | Protect electronic health information created or maintained by the certified EHR technology through the implementation of appropriate technical capabilities | Conduct or review a security risk analysis per 45 CFR 164.308 (a) (1) and implement security updates as necessary and correct identified security deficiencies as part of its risk management process | | | Yes |
| MENU SET | | | | | | | | |
| Select 5 Measures that includes one from Population Health – The other 5 Measures defer to Stage 2 | | | | | | | | |
| 16 | Improving quality, safety, efficiency, and reducing health disparities | Implement drug-formulary checks | Enabled | Implement drug-formulary checks | The EP has enabled this functionality and has access to at least one internal or external drug formulary for the entire EHR reporting period | | | Yes |
| 17 | | Lab Results into EHR | 40% | Incorporate clinical lab-test results into certified EHR technology as structured data | More than 40% of all clinical lab tests results ordered by the EP during the EHR reporting period whose results are either in a positive/negative or numerical format are incorporated in certified EHR technology as structured data | | X | |
| 18 | | Patient List | One List | Generate lists of patients by specific conditions to use for quality improvement, reduction of disparities, research or outreach | Generate at least one report listing patients of the EP with a specific condition. | | | Yes |
| 19 | | Patient Reminders | 20% | Send reminders to patients per patient preference for preventive/ follow up care | More than 20% of all unique patients 65 years or older or 5 years old or younger were sent an appropriate reminder during the EHR reporting period | | X | |
| 20 | Engage patients and families in their health care | Timely Electronic Access to Health Information | 10% | Provide patients with timely electronic access to their health information (including lab results, problem list, medication lists, medication allergies) within four business days of the information being available to the EP | More than 10% of all unique patients seen by the EP are provided timely (available to the patient within four business days of being updated in the certified EHR technology) electronic access to their health information subject to the EP's discretion to withhold certain information | X | | |
| 21 | | Patient Specific Education | 10% | Use certified EHR technology to identify patient-specific education resources and provide those resources where required and accepted | More than 10% of all unique patients seen by the EP are provided patient-specific education resources | X | | |
| 22 | Improve Care Coordination | Medication Reconciliation | 50% | The EP who receives a patient from another setting of care or provider of care or believes an encounter is relevant should perform medication reconciliation | The EP performs medication reconciliation for more than 50% of transitions of care in which the patient is transitioned into the care of the EP | | X | |

| Meaningful Use - Stage 1 | | | | | | ©Afia Inc 2010 | | | |
|---|--------|--------------------------------------|-------------------------|---------------|---|---|----------------------------|--------------------------------------|--------------------|
| The following outlines the FINAL Meaningful Use criteria for ARRA stimulus funding as of 7/13/2010. These are applicable to Eligible Professionals Only | | | | | | | | | |
| | Number | Outcome Priority | MU Category | Brief Measure | Definition | Measure | Unique Patient Denominator | Actions in Certified EHR Denominator | Yes/No Attestation |
| | 23 | | Summary of Care | 50% | The EP who transitions their patient to another setting of care or provider of care or refers their patient to another provider of care should provide summary of care record for each transition of care or referral | The EP who transitions or refers their patient to another setting of care or provider of care provides a summary of care record for more than 50% of transitions of care and referrals | | X | |
| | 24 | Improve population and public health | Immunization Registries | One Test | Capability to submit electronic data to immunization registries or Immunization Information System and actual submission in accordance with applicable law and practice | Performed at least one test of certified EHR technology's capacity to submit electronic data to immunization registries and follow up submission if the test is successful (unless none of the immunization registries to which the EP submits such information have the capacity to receive the information electronically) | | | Yes |
| | 25 | | Syndromic Surveillance | One Test | Capability to submit electronic syndromic surveillance data to public health agencies and actual submission in accordance with applicable law and practice | Performed at least one test of certified EHR technology's capacity to provide electronic syndromic surveillance data to public health agencies and follow-up submission if the test is successful (unless none of the public health agencies to which an EP submits such information have the capacity to receive the information electronically) | | | Yes |

Ambulatory Clinical Quality Measures

NQF 0001 Asthma Assessment

Title: Asthma Assessment Description: Percentage of patients aged 5 through 40 years with a diagnosis of asthma and who have been seen for at least 2 office visits, who were evaluated during at least one office visit within 12 months for the frequency (numeric) of daytime and nocturnal asthma symptoms.

NQF 0002 Pharyngitis- Children

Title: Appropriate Testing for Children with Pharyngitis Description: Percentage of children 2-18 years of age who were diagnosed with pharyngitis, dispensed an antibiotic and received a group A streptococcus (strep) test for the episode.

NQF 0004 Alcohol and Drug Dependence

Title: Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement Description: The percentage of adolescent and adult patients with a new episode of alcohol and other drug (AOD) dependence who initiate treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or partial hospitalization within 14 days of the diagnosis and who initiated treatment and who had two or more additional services with an AOD diagnosis within 30 days of the initiation visit.

NQF 0012 Prenatal Care: HIV Screening

Title: Prenatal Care: Screening for Human Immunodeficiency Virus (HIV) Description: Percentage of patients, regardless of age, who gave birth during a 12-month period who were screened for HIV infection during the first or second prenatal care visit.

NQF 0013 Hypertension: Blood Pressure Measurement

Title: Hypertension: Blood Pressure Measurement Description: Percentage of patient visits for patients aged 18 years and older with a diagnosis of hypertension who have been seen for at least 2 office visits, with blood pressure (BP) recorded.

NQF 0014 Prenatal Care: Anti-D immune Globulin

Title: Prenatal Care: Anti-D Immune Globulin Description: Percentage of D (Rh) negative, unsensitized patients, regardless of age, who gave birth during a 12-month period who received anti-D immune globulin at 26-30 weeks gestation.

NQF 0018 Controlling High Blood Pressure

Title: Controlling High Blood Pressure Description: The percentage of patients 18-85 years of age who had a diagnosis of hypertension and whose BP was adequately controlled during the measurement year

NQF 0024 Youth Weight Assessment

Title: Weight Assessment and Counseling for Children and Adolescents Description: Percentage of patients 2 -17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or OB/GYN and who had evidence of BMI percentile documentation, counseling for nutrition and counseling for physical activity during the measurement year.

NQF 0027 Tobacco Use Cessation

Title: Smoking and Tobacco Use Cessation, Medical assistance: a. Advising Smokers and Tobacco Users to Quit, b. Discussing Smoking and Tobacco Use Cessation Medications, c. Discussing Smoking and Tobacco Use Cessation Strategies Description: Percentage of patients 18 years of age and older who were current smokers or tobacco users, who were seen by a practitioner during the measurement year and who received advice to quit smoking or tobacco use or whose practitioner recommended or discussed smoking or tobacco use cessation medications, methods or strategies.

NQF 0028 Preventive Care: Tobacco Use Assessment and Cessation

Title: Preventive Care and Screening Measure Pair: a. Tobacco Use Assessment, b. Tobacco Cessation Intervention Description: Percentage of patients aged 18 years and older who have been seen for at least 2 office visits who were queried about tobacco use one or more times within 24 months b. Percentage of patients aged 18 years and older identified as tobacco users within the past 24 months and have been seen for at least 2 office visits, who received cessation intervention.

NQF 0031 Breast Cancer Screening

Title: Breast Cancer Screening Description: Percentage of women 40-69 years of age who had a mammogram to screen for breast cancer.

NQF 0032 Cervical Cancer Screening

Title: Cervical Cancer Screening Description: Percentage of women 21-64 years of age, who received one or more Pap tests to screen for cervical cancer

NQF 0033 Chlamydia Screening for Women

Title: Chlamydia Screening for Women Description: Percentage of women 15- 24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement year.

NQF 0034 Colorectal Cancer Screening

Title: Colorectal Cancer Screening Description: Percentage of adults 50-75 years of age who had appropriate screening for colorectal cancer.

NQF 0036 Appropriate Medications for Asthma

Title: Use of Appropriate Medications for Asthma Description: Percentage of patients 5 - 50 years of age who were identified as having persistent asthma and were appropriately prescribed medication during the measurement year. Report three age stratifications (5-11 years, 12-50 years, and total).

NQF 0038 Childhood Immunization Status

Title: Childhood Immunization Status Description: Percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV), one measles, mumps and rubella (MMR); two H influenza type B (HiB); three hepatitis B (Hep B); one chicken pox (VZV); four pneumococcal conjugate (PCV); two hepatitis A (Hep A); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday. The measure calculates a rate for each vaccine and nine separate combination rates.

NQF 0041 Influenza Immunization

Title: Preventive Care and Screening: Influenza Immunization for Patients ≥ 50 Years Old Description: Percentage of patients aged 50 years and older who received an influenza immunization during the flu season (September through February).

NQF 0043 Pneumonia Vaccination

Title: Pneumonia Vaccination Status for Older Adults Description: Percentage of patients 65 years of age and older who have ever received a pneumococcal vaccine.

NQF 0047 Asthma Pharmacologic Therapy

Title: Asthma Pharmacologic Therapy Description: Percentage of patients aged 5 through 40 years with a diagnosis of mild, moderate, or severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment.

NQF 0052 Use of Imaging Study: Low Back Pain

Title: Low Back Pain: Use of Imaging Studies Description: Percentage of patients with a primary diagnosis of low back pain who did not have an imaging study (plain x-ray, MRI, CT scan) within 28 days of diagnosis.

NQF 0055 Diabetes: Eye Exam

Title: Diabetes: Eye Exam Description: Percentage of patients 18 -75 years of age with diabetes (type 1 or type 2) who had a retinal or dilated eye exam or a negative retinal exam (no evidence of retinopathy) by an eye care professional.

NQF 0056 Diabetes: Foot Exam

Title: Diabetes: Foot Exam Description: The percentage of patients aged 18 - 75 years with diabetes (type 1 or type 2) who had a foot exam (visual inspection, sensory exam with monofilament, or pulse exam).

NQF 0059 Diabetes Control: Hemoglobin A1c $>9.0\%$

Title: Diabetes: Hemoglobin A1c Poor Control Description: Percentage of patients 18 - 75 years of age with diabetes (type 1 or type 2) who had hemoglobin A1c $> 9.0\%$.

NQF 0061 Diabetic Patients who elevated mmhg V140/90

Title: Diabetes: Blood Pressure Management Description: Percentage of patients 18 - 75 years of age with diabetes (type 1 or type 2) who had blood pressure <140/90 mmHg.

NQF 0062 Nephropathy Screening- Urine

Title: Diabetes: Urine Screening Description: Percentage of patients 18 - 75 years of age with diabetes (type 1 or type 2) who had a nephropathy screening test or evidence of nephropathy.

NQF 0064 Diabetes Control: LDL < 100mg/dl

Title: Diabetes: Low Density Lipoprotein (LDL) Management and Control Description: Percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had LDL-C < 100 mg/dL).

NQF 0067 Antiplatelet Therapy

Title: Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD Description: Percentage of patients aged 18 years and older with a diagnosis of CAD who were prescribed oral antiplatelet therapy.

NQF 0068 Ischemic Vascular Disease: Aspirin or other Antithrombotic

Title: Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic Description: Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) from January 1-November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year and who had documentation of use of aspirin or another antithrombotic during the measurement year.

NQF 0070 Coronary Artery Disease: Beta Blocker Therapy Post Myocardial Infarction

Title: Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) Description: Percentage of patients aged 18 years and older with a diagnosis of CAD and prior MI who were prescribed beta-blocker therapy.

NQF 0073 Blood Pressure Management: Ischemic Valve Disease

Title: Ischemic Vascular Disease (IVD): Blood Pressure Management Description: Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) from January 1- November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year and whose recent blood pressure is in control (<140/90 mmHg).

NQF 0074 Coronary Artery Disease: Lipid Lowering Therapy

Title: Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol Description: Percentage of patients aged 18 years and older with a diagnosis of CAD who were prescribed a lipid-lowering therapy (based on current ACC/AHA guidelines).

NQF 0075 IVD: Complete Lipid Panel and LDL Control

Title: Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control. Description: Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous transluminal angioplasty (PTCA) from January 1-November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year and who had a complete lipid profile performed during the measurement year and whose LDL-C<100 mg/dL.

NQF 0081 Heart Failure: ACE/ ARB Therapy For LVSD (LVEF <40%)

Title: Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) Description: Percentage of patients aged 18 years and older with a diagnosis of heart failure and LVSD (LVEF< 40%) who were prescribed ACE inhibitor or ARB therapy.

NQF 0083 Heart Failure: Beta Blocker for LVSD

Title: Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) Description: Percentage of patients aged 18 years and older with a diagnosis of heart failure who also have LVSD (LVEF < 40%) and who were prescribed beta- blocker therapy.

NQF 0084 Heart Failure: Warfarin Therapy

Title: Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation Description: Percentage of all patients aged 18 years and older with a diagnosis of heart failure and paroxysmal or chronic atrial fibrillation who were prescribed warfarin therapy.

NQF 0086 Primary Open Angle Glaucoma

Title: Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation Description: Percentage of patients aged 18 years and older with a diagnosis of POAG who have been seen for at least two office visits who have an optic nerve head evaluation during one or more office visits within 12 months.

NQF 0088 Diabetic Retinopathy: Macular Edema

Title: Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy Description: Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema during one or more office visits within 12 months.

NQF 0089 Diabetes Management: Retinopathy Screening

Title: Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care Description: Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed with documented communication to the physician who manages the ongoing care of the patient with diabetes mellitus regarding the findings of the macular or fundus exam at least once within 12 months.

NQF 0105 Depression Management

Title: Anti-depressant medication management: (a) Effective Acute Phase Treatment,(b)Effective Continuation Phase Treatment Description: The percentage of patients 18 years of age and older who were diagnosed with a new episode of major depression, treated with antidepressant medication, and who remained on an antidepressant medication treatment.

NQF 0385 Colon Cancer: Chemotherapy

Title: Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients Description: Percentage of patients aged 18 years and older with Stage IIIA through IIIC colon cancer who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy, or have previously received adjuvant chemotherapy within the 12-month reporting period.

NQF 0387 Breast Cancer: Hormonal Therapy

Title: Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer Description: Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period.

NQF 0389 Prostate Cancer: Avoid overuse of Bone Scan

Title: Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients Description: Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer.

NQF 0421 Adult Weight Screening

Title: Adult Weight Screening and Follow-Up Description: Percentage of patients aged 18 years and older with a calculated BMI in the past six months or during the current visit documented in the medical record AND if the most recent BMI is outside parameters, a follow-up plan is documented.

NQF 0575 Diabetes Control: Hemoglobin A1c <8.0%

Title: Diabetes: Hemoglobin A1c Control (<8.0%). Description: The percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had hemoglobin A1c <8.0%.